Journal of Allergy and Clinical Immunology Global, Год журнала: 2024, Номер 4(1), С. 100379 - 100379
Опубликована: Дек. 7, 2024
Язык: Английский
Allergy, Год журнала: 2024, Номер unknown
Опубликована: Сен. 16, 2024
Abstract Background In Europe, Omalizumab (anti‐IgE) is indicated for the treatment of moderate to severe asthma, but not IgE‐mediated food allergy (FA). Objective We assessed impact on efficacy, safety, and quality life (FA‐QoL) in patients with asthma who have a history anaphylaxis peanut, tree nuts, fish, egg, milk, and/or wheat. Methods Food‐allergic children (6–18 years) underwent oral challenges (OFCs) establish threshold reaction culprit food(s) at baseline (T0) 4‐month intervals (T1, T2, T3) during their first year Omalizumab. recorded number severity food‐allergic reactions, Asthma Control Test (ACT) scores, FA‐QoL, total IgE levels. Results 65 allergic 107 foods, No Observed Adverse Events Level (NOAEL) T1 increased: 243‐ 488‐fold fresh baked respectively; 172‐ 134‐fold raw egg; 245‐fold hazelnut; 55‐fold peanut; 31‐fold wheat; 10‐fold fish. Full tolerance was achieved 66.4% OFCs T1, 58.3% 75% T3. Ninety‐five foods were liberalized diet 55 patients; remaining 12 introduced by 10 least traces. Throughout study, 40 out able get free diet. ACT increased from 17 (Q1‐Q3: 15–17) 23.6 23–25). The FA‐QoL score ≤12 years decreased 4.63 ± 0.74 2.02 1.13, adolescents 4.68 0.92 1.90 1.50. Conclusions During therapy, safe reintroduction allergenic feasible. Trial Registration Number ClinicalTrials.gov , NCT06316414.
Язык: Английский
Процитировано
4
Social Science & Medicine, Год журнала: 2025, Номер unknown, С. 118085 - 118085
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
Medicina, Год журнала: 2024, Номер 60(6), С. 954 - 954
Опубликована: Июнь 8, 2024
Cannabis allergy is a relatively new phenomenon described in the 1970s. Its increased frequency has been observed over last years due to increasing therapeutic and recreational use of cannabis-based products. Sensitization possibly leading symptoms can occur not only through smoking cannabis, but also ingestion, inhalation pollen, or direct contact. The severity varies from benign pruritus anaphylaxis. There scant information available support clinicians throughout entire process, starting diagnosis ending treatment. In this review, we present six cases patients whom molecular vitro testing revealed sensitization cannabis extract and/or cannabis-derived nsLTP molecules (Can s 3). Based on these cases, raise important questions regarding topic. article discusses current proposals highlights importance further research asymptomatic allergens, which may be ascertained some percentage population.
Язык: Английский
Процитировано
2
Antibodies, Год журнала: 2024, Номер 13(3), С. 58 - 58
Опубликована: Июль 16, 2024
Immunoglobulin E (IgE) plays a critical role for the immune system, fighting against parasites, toxins, and cancer. However, when it reacts to allergens without proper regulation, can cause allergic reactions, including anaphylaxis, through process initiated by effector cells such as basophils mast cells. These display IgE on their surface, bound high-affinity receptor FcεRI. A cross-linking antigen then triggers degranulation release of inflammatory mediators from Therapeutic monoclonal anti-IgE antibodies omalizumab, disrupt this are used manage IgE-related conditions severe asthma chronic spontaneous urticaria. Interestingly, naturally occurring autoantibodies circulate at surprisingly high levels in healthy humans mice may thus be instrumental regulating activity. Although many open questions remain, recent studies have shed new light regulators mechanism action. Here, we summarize latest insights natural autoantibodies, compare functional features therapeutic autoantibodies.
Язык: Английский
Процитировано
2
Journal of Allergy and Clinical Immunology, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 1, 2024
Язык: Английский
Процитировано
1
Journal of Allergy and Clinical Immunology, Год журнала: 2024, Номер 155(1), С. 62 - 69.e1
Опубликована: Ноя. 22, 2024
Язык: Английский
Процитировано
1
Allergy, Год журнала: 2024, Номер unknown
Опубликована: Сен. 28, 2024
Abstract Peanut allergy treatment options remain limited, but novel approaches are being studied, including epicutaneous immunotherapy (EPIT). EPIT uses the cutaneous immune system to promote tolerance food allergens. Viaskin™ Peanut, an approach in late‐stage clinical development occlusive patch with a condensation chamber that enables natural epidermal water loss solubilize dry antigen on patch, which is then absorbed and captured by skin Langerhans cells. This form of does not require disruption barrier, thus avoiding proinflammatory cytokine response targeting nonvascularized epidermis limiting systemic allergen exposure. Extensive preclinical research suggests Viaskin has distinct mechanism desensitization, potential for disease modification, driven unique population regulatory T Numerous studies have demonstrated desensitization reductions reaction severity, particularly children aged 1 through 11 years, as well favorable safety profile mostly mild‐to‐moderate reactions were observed decrease over time. may be therapeutic option peanut clinically practical long‐term efficacy tolerability.
Язык: Английский
Процитировано
0
Annals of Allergy Asthma & Immunology, Год журнала: 2024, Номер unknown
Опубликована: Окт. 1, 2024
Язык: Английский
Процитировано
0
Allergologie select, Год журнала: 2024, Номер 8(01), С. 365 - 406
Опубликована: Янв. 1, 2024
The development of targeted therapies for atopic diseases, urticaria, and angioedema with biologics is progressing rapidly: New "targets" clinical-therapeutic relevance have been identified, the corresponding antibodies developed, tested in clinical trials, approved therapy. These include anti-IgE antibody omalizumab (also effective treatment urticaria), anti-IL-4/13 receptor-specific dupilumab, two anti-IL-13 lebrikizumab tralokinumab, anti-TSLP tezepelumab, anti-IL-5 mepolizumab reslizumab, anti-IL5 benralizumab diseases. For hereditary angioedema, C1 inhibitor lanadelumab (directed against kallikrein) also long as addition to low-molecular substances. Other therapeutic are various stages development. Furthermore, range indications some very has successfully expanded additional In this context, first results on biologic therapy food allergy eosinophilic esophagitis interesting. Biologics that address different target structures increasingly being administered combination, either simultaneously or sequentially, order achieve optimal efficacy. A developing area use children observation immunological non-immunological side effects. cases, new unexpected effects hypersensitivity reactions emerged, which turn raise pathomechanistic questions, such conjunctivitis dupilumab therapy, only appears occur dermatitis but not other dermatology, paradoxical described under biologics. And immune type alpha epsilon (hypersensitivity reactions) continue be a clinically relevant problem, whereby selection an alternative agent challenge diagnostics support yet sufficiently incorporated into routine work.
Язык: Английский
Процитировано
0
Annals of Allergy Asthma & Immunology, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 1, 2024
Язык: Английский
Процитировано
0